Apadoline

Apadoline
Clinical data
Other namesRP-60180; RP60180; RP-60,180; RP-60180A
Drug classκ-Opioid receptor agonist
ATC code
  • None
Identifiers
  • N-propyl-10-[(2R)-1-pyrrolidin-1-ylpropan-2-yl]phenothiazine-2-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H29N3OS
Molar mass395.57 g·mol−1
3D model (JSmol)
  • CCCNC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2[C@H](C)CN4CCCC4
  • InChI=1S/C23H29N3OS/c1-3-12-24-23(27)18-10-11-22-20(15-18)26(17(2)16-25-13-6-7-14-25)19-8-4-5-9-21(19)28-22/h4-5,8-11,15,17H,3,6-7,12-14,16H2,1-2H3,(H,24,27)/t17-/m1/s1
  • Key:KXMAIWXPZGQNCR-QGZVFWFLSA-N

Apadoline (INNTooltip International Nonproprietary Name; developmental code name RP-60180) is a κ-opioid receptor agonist and experimental analgesic which was under development for the treatment of cancer pain but was never marketed. It produces effects and adverse effects in humans including analgesia, drowsiness, and headache, among others. Its affinities (Ki) for the opioid receptors are 0.55 nM for the κ-opioid receptor, 11.4 nM for the δ-opioid receptor, and 57 nM for the μ-opioid receptor. Apadoline was first described in the scientific literature by 1990. It was under development by Rhône-Poulenc in the 1990s and reached phase 2 clinical trials prior to the discontinuation of its development. An analogue with greater potency, RP-61127, has also been described.

See also